Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of XYDALBA™. Additional terms of the agreement were not disclosed.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”